Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7701MR)

This product GTTS-WQ7701MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7701MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8875MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ5385MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ5232MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ7340MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ10947MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ8544MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ3239MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ7310MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW